ArticleCureus2025
Prospective Evaluation of Low-Dose Theophylline as an Add-On Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is still a big health concern across the globe, and better pharmacological techniques are needed to better control the condition.
objectiveThis study aimed to find out whether low-dose theophylline may help COPD patients get better when used with other treatments. METHODOLOGY: This prospective observational research was place at the Department of Pulmonology of Abbas Institute of Medical Sciences (AIMS) in Muzaffarabad, Pakistan, from April 2023 to March 2024. A total of 132 individuals with stable moderate to severe COPD who were at least 40 years old were recruited and given low-dose theophylline (300 mg once a day) along with their normal inhaled treatment. We checked up on the patients every three months for a year. The main results were spirometric measures (FEV₁, FVC, FEV₁/FVC), COPD Assessment Test (CAT) scores, Modified Medical Research Council (mMRC) dyspnea grades, how often exacerbations happened, how well people followed their treatment, and any side effects. We used IBM SPSS Statistics for Windows, Version 26.0 (Released 2019; IBM Corp., Armonk, New York, United States), to look at the data and ran repeated measures ANOVA and chi-squared testing.
resultsThe mean FEV₁ increased from 1.12±0.25 L at baseline to 1.33±0.28 L at 12 months (p<0.001) and FVC increased from 2.01±0.42 L to 2.20±0.44 L (p<0.01). CAT scores dropped from 22.8 to 15.6 and mMRC grades from 2.92 to 2.02 (both p<0.001). A total of 59 patients (44.7%) experienced no exacerbations during follow-up. Therapy adherence >80% was achieved in 117 patients (88.6%), and 94 patients (71.2%) reported no adverse effects.
conclusionLow-dose theophylline may offer a well-tolerated, cost-effective adjunct to conventional COPD treatment in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.